患者来源肿瘤类器官在抗肿瘤药物研发中的应用  

Application of patient-derived tumor organoids in the development of anti-tumor drugs

作　　者：李彦佼 张佳月 房艳华 梁珊珊 王若雨 LI Yanjiao;ZHANG Jiayue;FANG Yanhua;LIANG Shanshan;WANG Ruoyu(The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor of Liaoning Province,Dalian 116001,China;School of Bioengineering,Dalian University of Technology,Dalian 116024,China)

机构地区：[1]辽宁省乳腺及消化肿瘤分子标志物高通量筛选及靶向药物转化重点实验室,辽宁大连116001 [2]大连理工大学生物工程学院,辽宁大连116024

出　　处：《大连医科大学学报》2024年第3期236-241,共6页Journal of Dalian Medical University

基　　金：国家自然科学基金项目(82172822);大连市尖端及领军人才支持计划(2021RD02)。

摘　　要：抗肿瘤药物的开发一直面临研发周期长、体内药效差异大和个体间疗效差异等问题。患者来源肿瘤类器官(PDTO)是肿瘤细胞的三维培养物,可以长期扩增,模拟体内肿瘤特征及肿瘤细胞异质性,近年来在高通量药物筛选及个体化医学领域展现出巨大潜力。本文对PDTO模型的构建及PDTO在抗肿瘤药物筛选、新药研发中的应用及现阶段存在的问题进行综述,为医药工业和相关肿瘤生物学领域的深入研究提供参考。The development of anti-tumor drugs has long faced challenges such as lengthy development cycles,significant variability in drug efficacy in vivo,and differences in effectiveness among individuals.Patient-derived tumor organoids(PDTO)are three-dimensional cultures of tumor cells that can be expanded for a long time,simulating the characteristics of in vivo tumors and tumor cell heterogeneity.In recent years,PDTOs have shown great potential in the field of high-throughput drug screening and personalized medicine.This article reviews the construction of PDTO models and their application in anti-tumor drug screening,new drug research and development,and the current issues faced in this field,aiming to provide a reference for in-depth research in the pharmaceutical industry and related areas of tumor biology.

关 键 词：肿瘤类器官 抗肿瘤药物研发 高通量药物筛选 个性化医疗 

分 类 号：R73-3[医药卫生—肿瘤]